Shield Provides Full Year Trading Update and Reports Progress
SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A....
What Investors Should Know About Shield Therapeutics` Financial Strength
U.K.-based Shield Therapeutics has an interesting problem. The company recently went public, raising a bit more than $47 million, less than the apparent $170 million it wanted. Yet, the company has a drug in Phase III clinical trials in Europe that looks very promising for an unmet need. So what to do? One possibility is look for a partner with money, suggests George Ronan, writing for Market Exclusive. But who?